KEY-NOTE SPEAKER: Prof. Igor Resnick

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 
 
Dear BSYSB Participants,
We are proud to reveal the second key-note speaker of the conference - Professor Igor Resnick - a deputy director of the Department of Bone Marrow Transplantation and Immunotherapy at Hadassah University Hospital in Jerusalem, Israel, who is going to present his lecture on the topic:
 HCT for non malignant disease

Curriculum Vitae of Professor Igor Resnick, MD, PhD
Born on the 15th of May 1952 in the city of Odessa, Ukraine. Graduated with honors from the Medical Institute of Docenk, Odessa in 1975. Worked in the Institute of pediatrics in the Academy of Medical Sciences of the Soviet Union (Moscow) from 1976 to 1993. Obtained a specialty in pediatrics in 1978. Defended a thesis for a PhD in 1988.
Responsible for the Department of Immunology at the scientific institute of Pediatric Hematology, oncology and immunology at Moscow from 1993 to 2003 and a consultant in the aforementioned department since. As of 2009 – a member of the International Council in the same institution. A Pediatrics Professor in the state University of Moscow from 1995-2992. Specialist in alergology and clinical immunology since 2000, the year when he became a professor. An honorary professor in the state University of Moscow since 2009.
Moved to Israel in 1999 to work in the University Medical Center Hadassah. Senior associate in the Bone marrow transplantation and cancer immunotherapy department. Following additional specializations, he became a certified pediatrics expert (2000) and alergology and immunology expert (2006) in Israel in 2000. An associate professor since 2007 and an academic professor since 2011 in the Hebrew university in Jerusalem, Israel. A honorary guest lecturer in several Italian Universities.
Specialized in various neonatology and pediatrict, immunology and bone marrow transplantation courses in children in the Instituto Materno Infantile and Hospita Fatetebenefratelli, Palermo, Italy (1992-1993), Cpedali Civili, Breschia, Italy (1997) and the Harvard Medical School, Centre of Blood Research and Children's Hospital, Boston, USA (1995), participated in scientific immunological research at INSERM U430, Paris, France (1996).
Responsible for his own scientific laboratory in the Hebrew University in Jerusalem since 2007, Supervisor of over 20 students and researches from Israel, India and Russia.  Member of the scientific board and reviewer of several scientific journals.
Publications:
Author and co-author of over 350 scientific works, 200 of which – full-text articles. His main interest lie in the field of Biology and more precisely in the clinic implementation of the transplantation of haematopoetic and mesenchyme stem cells, several rare genetic diseases, notably primary immune deficiencies, microsomes during distant intercellular communication (in vitro and during biological models), stem-cell restauration in brain injuries (trauma, amyotrophic lateral sclerosis, multiple sclerosis, neurodegenerative disorders)(mechanisms and clinical implementation), mechanisms of acceptance (rejection).
  1. Lucotte G, Lagarde JP, and M. Kinali, C. Castellan, E. Sukarova, S. Jablonska, B. Tuysuz, I.B. Resnick (2007). Mutations of the NOGGIN and of the Activin A type I Receptor genes in Fibrodisplasia Ossificans Progressiva (FOP). Cenetic Counseling, vol. 18 (3): 349-352.( 0.395; 97/106; 5;5)
  2. Resnick IB, Tsirigotis PD, Shapira MY, Aker M, Bitan M, Samuel S, Abdul-Hai A, Ackerstein A, Or R, Slavin S. ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant. 2008 Apr;14(4):409-17.(.3.275; 24/66; 53/134; 8/25; 7;7)
  3. Gurevitch OPI, Slavin S, Resnick IB, Khitrin S, Feldman A. Mesenchymal progenitor cells in red and yellow bone marrow. Folia Biol (Praha) 2009; 55(1):27-34. (0)
  4. Cohen-Daniel L, Zakay-Rones Z, Resnick IB, Shapira MY, Dorozhko M, Mador N, Greenbaum E, Wolf DG. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient. J Clin Virol. 2009 Feb; 44(2):138-40. Epub 2009 Jan 20.( 4.023; 8/33; 3;3)
  5. Shapira MY, Resnick IB, Dray L, Aker M, Stepensky P, Elad S, Gesundeheidt B, Samuel S, Or R.A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy. 2009; 11(1):61-7.( 2.925; 52/160; 9/13; 103/178; 29/66; 34/106; 6;6)
  6. Vagima Y, Avigdor A, Goichberg P, Shivtiel S, Tesio M, Kalinkovich A, Golan K, Dar A, Kollet O, Petit I, Perl O, Rosenthal E, Resnick I, Hardan I, Gellman YN, Naor D, Nagler A, Lapidot T. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest. 2009 Mar;119(3):492-503. (14.152; 3/106; 16;16)
  7. Kedmi M, Resnick IB, Dray L, Aker M, Samuel S, Gesundheit B, Slavin S, Or R, Shapira MY. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant. 2009 Apr; 15(4):483-9. (.3.275; 24/66; 53/134; 8/25; 4;4)
  8. Resnick I, Stepensky P, Elkin G, Barkatz C, Gurevich O, Prigozhina T, Pikarsky E, Waldman E, Amar A, Samuel S, Shapira M, Weintraub M, Or R. MSC for the improvement of hematopoietic engraftment. Bone Marrow Transplant. 2010 Mar; 45(3):605-6. Epub 2009 Aug 31.( 3.660; 20/66; 40/134 ; 57/185; 1;1)
  9. Tsirigotis P, Shapira MY, Or R, Bitan M, Samuel S, Gesundheit B, Ackerstein A, Abdul-Hai A, Slavin S, Resnick IB. The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin. Bone Marrow Transplant. 2010 Jul;45(7):1189-96Nov [Epub ahead of print] ( 3.660; 20/66; 40/134 ; 57/185;1;1)
  10. Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB. IL-2-inducible T cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2011; 96(3):472-6. Epub 2010 Nov 25. (6.532; 7/66; 2;1)
  11. Stepensky P, Shapira MY, Balashov D, Trakhtman P, Skorobogatova E, Rheingold L, Brooks R, Revel-Vilk S, Weintraub M, Stein J, Maschan A, Or R, Resnick IB. Bone marrow transplantation for Fanconi anemia using fludarabine - based conditioning Biol Blood Marrow Transplant. 2011 Sep;17(9):1282-8. Epub 2011 Jan 8. (.3.275; 24/66; 53/134; 8/25; 0:0)
  12. Gregory Elkin, Tatyana B. Prigozhina, Shimon Slavin, Olga Gurevitch, Sofia Khitrin, Igor B. Resnick. Visualization of immune response kinetics in full allogeneic chimeras. Am J Blood Res 2011;1(2):110-118.(0)
  13. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-Bloom N, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).Am J Blood Res. 2013 Aug 19;3(3):225-38.
  14. Tsirigotis P, Resnick IB, Kapsimalli V, Dray L, Psarra E, Samuel S, Spyridonidis A, Konsta E, Vikentiou M, Or R, Slavin S, Shapira MY. Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. Immunotherapy. 2014 Apr;6(4):409-17. doi: 10.2217/imt.14.10.
  15. Kassis I, Barkatz C, Vaknin-Dembinsky A, Petrou P, Halimi M, Resnick I, Karussis D. (2015) Immunological Mechanisms and Biological Effects of Bone Marrow derived Mesenchymal Stem Cells (MSC) from Patients With MS, as Compared to Healthy Donors. Enliven: J Stem Cells Regen Med 1(1):008.
  16. Polina Y. Stepensky, Reuven Or, Michael Y Shapira, Shoshana Revel-Vilk, Jerry Stein, and Igor B. Resnick. Second bone marrow transplantation for patients with thalassemia: risks and benefits. Haematologica 2009 Sep; 94(9):1329-30. (6.532; 7/66; 2;1)
  17. Polina Stepensky, Ansgar S. Schulz, Georgia Lahr, Natalia Simanovsky, Rebecca Brooks, Simcha Samuel, Reuven Or, Michael Weintraub, Igor Resnick. Successful second haploidentical stem cell transplantation in osteopetrosis Bone Marrow Transplant, 2011 46(7); 1021-2. (3.660; 20/66; 40/134 ; 57/185; 0;0)
  18. Tsirigotis PD, Resnick IB, Shapira MY. The role of natural killer cells in hematopoietic stem cell transplantation. Ann Med. 2012; 44 (2): 130-45 (4.323; 16/153; 0;0)
  19. Pessach I, Resnick I, Shimoni A, Nagler A. G-CSF-primed BM for allogeneic SCT: revisited. Bone Marrow Transplant. 2015 Mar 2. doi: 10.1038/bmt.2015.25. Review. PubMed PMID: 25730185.
 Member of:
 The Medical association of Israel and the Bone-marrow transplantation Society. Member of the Committee of Primary immunodeficiencies at the WHO (1994-1998).